SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the first quarter ended March 31, 2020 via a press release on May 12, 2020.
About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio.Contact:Investors
Neera Ravindran, MD
Head of Investor Relations & Strategic Communications
[email protected]
+1-415-506-5256Media
Lindy Devereux
Scient PR
[email protected]
+1-646-515-5730
Bay Street News